Harvard Bioscience (HBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,445 | -6,880 | -288 | -1,249 | -1,079 |
| Depreciation Amortization | 3,818 | 1,918 | 7,901 | 5,909 | 3,960 |
| Income taxes - deferred | 1,040 | -123 | -330 | -498 | -303 |
| Accounts receivable | 3,587 | 1,506 | -4,294 | -727 | 323 |
| Accounts payable and accrued liabilities | -435 | 2,729 | 2,454 | N/A | 1,629 |
| Other Working Capital | -951 | 2,076 | -10,190 | -6,153 | -2,905 |
| Other Operating Activity | -4,790 | -3,212 | 6,009 | 3,863 | 180 |
| Operating Cash Flow | $-2,176 | $-1,986 | $1,262 | $1,145 | $1,805 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -913 | -471 | -1,195 | -837 | -357 |
| Purchase Sale Intangibles | N/A | N/A | -150 | -150 | -150 |
| Other Investing Activity | 0 | 0 | -150 | -150 | -150 |
| Investing Cash Flow | $-913 | $-471 | $-1,345 | $-987 | $-507 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 5,300 | 1,500 | 4,250 | 2,500 | N/A |
| Debt Repayment | -5,286 | -936 | -4,200 | -5,500 | -4,000 |
| Common Stock Issued | 282 | 31 | 3,314 | 2,909 | 2,759 |
| Other Financing Activity | -780 | -501 | -3,616 | -2,755 | -2,092 |
| Financing Cash Flow | $-484 | $94 | $-252 | $-2,846 | $-3,333 |
| Exchange Rate Effect | 11 | -25 | -161 | -81 | -45 |
| Beginning Cash Position | 7,821 | 7,821 | 8,317 | 8,317 | 8,317 |
| End Cash Position | 4,259 | 5,433 | 7,821 | 5,548 | 6,237 |
| Net Cash Flow | $-3,562 | $-2,388 | $-496 | $-2,769 | $-2,080 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,176 | -1,986 | 1,262 | 1,145 | 1,805 |
| Capital Expenditure | -913 | -471 | -1,195 | -837 | -357 |
| Free Cash Flow | -3,089 | -2,457 | 67 | 308 | 1,448 |